MARKET

CLLS

CLLS

Cellectis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

17.78
+0.52
+3.01%
After Hours: 17.78 0 0.00% 16:00 08/05 EDT
OPEN
17.14
PREV CLOSE
17.26
HIGH
17.78
LOW
17.07
VOLUME
110.79K
TURNOVER
--
52 WEEK HIGH
21.97
52 WEEK LOW
7.32
MARKET CAP
754.68M
P/E (TTM)
-11.3140
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CLLS stock price target is 31.90 with a high estimate of 50.00 and a low estimate of 11.00.

EPS

CLLS News

More
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020
* Enrollment ongoing in Phase 1 dose-escalation trial BALLI-01 in r/r B-ALL patients * Enrollment ongoing in Phase 1 dose-escalation trial AMELI-01 in r/r AML patients   * MELANI-01 trial in r/r MM patients on hold; Cellectis is actively working with th
GlobeNewswire · 5h ago
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT
NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced that it will report it
GlobeNewswire · 07/29 20:30
4 Companies That Could Upend the Pharma Industry
MotleyFool.com · 07/29 13:27
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing
NEW YORK, July 21, 2020 -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on.
GlobeNewswire · 07/21 20:30
Monthly information on share capital and company voting rights
GlobeNewswire · 07/10 23:04
Biotech IPO Nkarta triples in debut
Seeking Alpha - Article · 07/10 16:45
65 Biggest Movers From Yesterday
Gainers MOGU Inc. (NASDAQ: MOGU) shares climbed 104.8% to close at $5.92 on Tuesday.
Benzinga · 07/08 10:05
51 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 07/07 16:15

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About CLLS

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
More

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.